Alexander Spira

Assistant Professor

1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Alexander Spira is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Phosphatidylinositol 3-Kinase Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., Ojo, N. C., Caldwell, K., Abhyankar, J., Boucher, T., Hart, M. G., Makarov, V., De Montpreville, V. T., Mercier, O., Chan, T. A., Scagliotti, G. & 19 others, Bironzo, P., Novello, S., Karachaliou, N., Rosell, R., Anderson, I., Gabrail, N., Hrom, J., Limvarapuss, C., Choquette, K., Spira, A., Rousseau, R., Voong, C., Rizvi, N. A., Fadel, E., Frattini, M., Jooss, K., Skoberne, M., Francis, J. & Yelensky, R., Jan 1 2019, In : Nature Biotechnology. 37, 1, p. 55-71 17 p.

Research output: Contribution to journalArticle

Antigens
HLA Antigens
Peptides
Mass spectrometry
Tumors

Detection of NRG1 gene fusions in solid tumors

Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., Ma, P. C., Nieva, J. J., Spira, A., Vanderwalde, A. M., Wozniak, A. J., Kim, E. S. & Liu, S. V., Aug 15 2019, In : Clinical Cancer Research. 25, 16, p. 4966-4972 7 p.

Research output: Contribution to journalArticle

Open Access
Gene Fusion
Neoplasms
Incidence
Breast Neoplasms
RNA Sequence Analysis

Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors

Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N., Awad, M., Calvo, E., Moreno, V., Govindan, R., Spira, A., Gonzalez, M., Zhong, B., Santiago-Walker, A., Poggesi, I., Parekh, T., Xie, H., Infante, J. & Tabernero, J., Aug 15 2019, In : Clinical Cancer Research. 25, 16, p. 4888-4897 10 p.

Research output: Contribution to journalArticle

Fibroblast Growth Factor Receptors
Cholangiocarcinoma
Neoplasms
Hyperphosphatemia
Carcinoma

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor

Helman, E., Nguyen, M., Karlovich, C. A., Despain, D., Choquette, A. K., Spira, A., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B. & Simmons, A. D., Jan 1 2018, (Accepted/In press) In : Clinical Lung Cancer.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
DNA
Non-Small Cell Lung Carcinoma
Mutation
Genes

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Ojemuyiwa, M., Zeman, K., Spira, A., Oronsky, B., Ray, C., Trepel, J. B., Lee, M. J., Onyiuke, I. & Brzezniak, C., Jan 1 2018, (Accepted/In press) In : Clinical Case Reports.

Research output: Contribution to journalArticle

Neuroendocrine Carcinoma
Phase II Clinical Trials
Castration
Platinum
Prostate